Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) commences share repurchases on December 30, 2021, under the program mandated by the shareholders in the Annual General Meeting held on June 11, 2021. As per the mandate, the company is authorized to repurchase up to 3,882,210 H shares, representing 10% of its class H shares and 2.2% of its total issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The shares repurchased will be cancelled. The repurchases will be made out of the funds legally available for such purpose in accordance with all applicable laws, regulations, rules and/or requirements of the Hong Kong Stock Exchange or any other relevant governmental or regulatory authorities in the PRC. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 11, 2021, the company had 176,622,100 shares in issue, comprising 137,800,000 A shares and 38,822,100 H shares.